OraSure Technologies (NASDAQ:OSUR) Rating Lowered to Hold at StockNews.com

OraSure Technologies (NASDAQ:OSUR) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

OraSure Technologies Stock Performance

Shares of OraSure Technologies stock opened at $3.57 on Tuesday. The firm’s 50-day simple moving average is $3.77 and its 200-day simple moving average is $4.00. OraSure Technologies has a twelve month low of $2.68 and a twelve month high of $7.43. The firm has a market cap of $266.30 million, a P/E ratio of 23.80 and a beta of 0.05.

Insider Transactions at OraSure Technologies

In related news, CEO Manner Carrie Eglinton bought 78,625 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was acquired at an average cost of $3.15 per share, with a total value of $247,668.75. Following the acquisition, the chief executive officer now owns 1,259,664 shares in the company, valued at approximately $3,967,941.60. This represents a 6.66 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Kenneth J. Mcgrath bought 64,000 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was bought at an average cost of $3.15 per share, with a total value of $201,600.00. Following the completion of the acquisition, the chief financial officer now owns 371,013 shares in the company, valued at $1,168,690.95. This represents a 20.85 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 190,284 shares of company stock valued at $600,348. Corporate insiders own 3.40% of the company’s stock.

Institutional Investors Weigh In On OraSure Technologies

A number of large investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD grew its position in OraSure Technologies by 5.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 76,932 shares of the medical instruments supplier’s stock worth $278,000 after acquiring an additional 3,828 shares during the last quarter. Invesco Ltd. grew its position in OraSure Technologies by 3.4% during the 4th quarter. Invesco Ltd. now owns 127,526 shares of the medical instruments supplier’s stock worth $460,000 after acquiring an additional 4,240 shares during the last quarter. Tower Research Capital LLC TRC grew its position in OraSure Technologies by 202.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 5,234 shares during the last quarter. Legal & General Group Plc grew its position in OraSure Technologies by 32.3% during the 4th quarter. Legal & General Group Plc now owns 23,626 shares of the medical instruments supplier’s stock worth $85,000 after acquiring an additional 5,770 shares during the last quarter. Finally, Orion Portfolio Solutions LLC grew its position in OraSure Technologies by 10.7% during the 4th quarter. Orion Portfolio Solutions LLC now owns 61,170 shares of the medical instruments supplier’s stock worth $221,000 after acquiring an additional 5,929 shares during the last quarter. 93.50% of the stock is currently owned by institutional investors.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.